NanoFabTx^™ formulation kits and lipid mixes enable users to encapsulate a wide variety of therapeutic drug molecules for targeted or extended drug delivery without the need for lengthy trial-and-error optimization. NanoFabTx^™ kits provide an easy to use toolkit for encapsulating a variety of therapeutics in nanoparticles, microparticles, or liposomes. Drug encapsulated particles synthesized with the NanoFabTx^™ kits are suitable for biomedical research applications such as oncology, immuno-oncology, gene delivery and vaccine delivery.

The NanoFabTx^™ materials screening kit, for synthesis of polymeric nanoparticles, is a ready-to-use nanoformulation kit for the synthesis of nanoparticles for drug delivery. Poly(lactic-co-glycolic acid) (PLGA), poly(D,L-lactic acid) (PLA) and polycaprolactone (PCL) are biocompatible and biodegradable polymers that have been approved by the FDA for biomedical and pharmaceutical applications. This kit includes properly selected PLGA, PLA, and PCL polymers and stabilizer, allowing for rapid screening of optimal materials for enhanced drug loading and controlled drug release.

Comprehensive protocols for nanoparticle synthesis methods are included:

• A nanoprecipitation protocol to prepare drug-encapsulated nanoparticles in standard laboratory glassware.
• A microfluidics protocol using commercial platforms or syringe pumps.

The microfluidics protocol uses NanoFabTx^™ device kits (911593), which provide the microfluidics chips, fittings, and tubing required to get started with microfluidics-based synthesis (compatible microfluidics system or syringe pump required).

For more information, please refer to the protocol under the document section of this page.

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC